Published in Per Med on March 01, 2009
Genomic sequencing: assessing the health care system, policy, and big-data implications. Health Aff (Millwood) (2014) 1.27
Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique. Eur J Health Econ (2013) 0.92
Capacity building for assessing new technologies: approaches to examining personalized medicine in practice. Per Med (2010) 0.85
A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications. Breast Cancer Res (2012) 0.84
Economic evaluations of personalized medicine: existing challenges and current developments. Pharmgenomics Pers Med (2015) 0.82
Opportunities for translational epidemiology: the important role of observational studies to advance precision oncology. Cancer Epidemiol Biomarkers Prev (2015) 0.79
Do economic evaluations of targeted therapy provide support for decision makers? J Oncol Pract (2011) 0.78
Commercial Opportunities and Ethical Pitfalls in Personalized Medicine: A Myriad of Reasons to Revisit the Myriad Genetics Saga. Curr Pharmacogenomics Person Med (2013) 0.77
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med (2006) 9.85
The statistical basis of meta-analysis. Stat Methods Med Res (1993) 6.87
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2007) 2.33
A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol (2007) 2.09
PHARMAC and Herceptin for early-stage breast cancer in New Zealand: Herceptin or deception? N Z Med J (2006) 2.08
Trastuzumab: a pharmacoeconomic review of its use in early breast cancer. Pharmacoeconomics (2008) 2.04
PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer. N Z Med J (2007) 2.03
A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann Oncol (2005) 1.83
Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ (2007) 1.53
Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist (2008) 1.48
Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer (2007) 1.40
Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs (2002) 1.18
Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol (2007) 1.13
Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab? J Clin Oncol (2007) 1.03
Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Ann Oncol (2007) 0.99
Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model. Pharmacoeconomics (2007) 0.98
Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol (2007) 0.95
Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncol (2007) 0.93
Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium. Health Policy (2008) 0.92
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. Ann Oncol (2005) 0.89
Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis. Am J Clin Oncol (2008) 0.85
Patient demand and politics push Herceptin forward. CMAJ (2005) 0.83
Cardiotoxicity associated with the use of trastuzumab in breast cancer patients. Expert Rev Anticancer Ther (2007) 0.83
The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res Treat (2007) 0.83
Is trastuzumab a cost-effective treatment for breast cancer? Expert Rev Pharmacoecon Outcomes Res (2008) 0.82
Cost-effectiveness analysis of strategies for HER2 testing of breast cancer patients in France. Int J Technol Assess Health Care (2006) 0.80
PHARMAC responds on Herceptin assumptions and decisions. N Z Med J (2007) 0.78
How much will Herceptin really cost? The money is already there. BMJ (2006) 0.77
Breast Cancer Advocacy Coalition responds to the 'Herceptin or deception' article. N Z Med J (2006) 0.77
Roche responds to the 'Herceptin or deception' article. N Z Med J (2006) 0.77
How much will Herceptin really cost? Balancing local and national priorities is not new. BMJ (2006) 0.76
Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. J Clin Oncol (2014) 4.31
Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med (2005) 3.55
Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med (2011) 3.52
Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol (2005) 2.76
Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer (2009) 2.63
Effect of managed care insurance on the use of preventive care for specific ethnic groups in the United States. Med Care (2002) 2.34
Variation in access to health care for different racial/ethnic groups by the racial/ethnic composition of an individual's county of residence. Med Care (2004) 2.25
Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol (2008) 2.20
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol (2009) 1.88
Measuring patient preferences for colorectal cancer screening using a choice-format survey. Value Health (2007) 1.86
Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol (2008) 1.84
Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J Natl Cancer Inst (2010) 1.83
A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol (2011) 1.74
Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes (2014) 1.65
Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv Res (2006) 1.64
Shifting patterns in the interpretation of phase III clinical trial outcomes in advanced non-small-cell lung cancer: the bar is dropping. J Clin Oncol (2014) 1.61
The association of race, socioeconomic status, and health insurance status with the prevalence of overweight among children and adolescents. Am J Public Health (2003) 1.53
Rates and predictors of colorectal cancer screening. Prev Chronic Dis (2006) 1.31
Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care (2008) 1.30
The effect of area HMO market share on cancer screening. Health Serv Res (2004) 1.29
How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey. Health Econ (2009) 1.27
Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. J Clin Oncol (2009) 1.25
Discordant indigenous and provider frames explain challenges in improving access to arthritis care: a qualitative study using constructivist grounded theory. Int J Equity Health (2014) 1.23
A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. Oncologist (2010) 1.22
How the new medicare drug benefit could affect vulnerable populations. Health Aff (Millwood) (2006) 1.21
How does cost matter in health-care discrete-choice experiments? Health Econ (2011) 1.15
An experiment on simplifying conjoint analysis designs for measuring preferences. Health Econ (2003) 1.14
Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay. J Oncol Pract (2010) 1.14
The Alberta Hip and Knee Replacement Project: a model for health technology assessment based on comparative effectiveness of clinical pathways. Int J Technol Assess Health Care (2009) 1.13
Health technology assessment and private payers' coverage of personalized medicine. J Oncol Pract (2011) 1.10
Clinical outcomes of extensive stage small cell lung carcinoma patients treated with consolidative thoracic radiotherapy. Clin Lung Cancer (2011) 1.09
Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. J Thorac Oncol (2007) 1.07
Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling. Genet Med (2011) 1.07
Women's out-of-pocket expenditures and dispensing patterns for oral contraceptive pills between 1996 and 2006. Contraception (2010) 1.06
KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. J Thorac Oncol (2013) 1.05
Moving beyond the typologies of managed care: the example of health plan predictors of screening mammography. Health Serv Res (2004) 1.03
A health services research agenda for cellular, molecular and genomic technologies in cancer care. Public Health Genomics (2009) 1.01
Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer. Chest (2005) 1.01
Barriers and challenges to global clinical cancer research. Oncologist (2013) 1.01
Locoregional failures following thoracic irradiation in patients with limited-stage small cell lung carcinoma. Radiother Oncol (2012) 1.00
Development and evaluation of a decision aid for patients considering first-line chemotherapy for metastatic breast cancer. Health Expect (2008) 1.00
Challenges to implementation of an epidermal growth factor receptor testing strategy for non-small-cell lung cancer in a publicly funded health care system. J Thorac Oncol (2013) 1.00
Impact and feasibility of a comprehensive geriatric assessment in the oncology setting: a pilot study. Am J Clin Oncol (2012) 0.98
Does patient cost sharing matter? Its impact on recommended versus controversial cancer screening services. Am J Manag Care (2004) 0.97
Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial. J Clin Oncol (2009) 0.96
Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer. Lung Cancer (2011) 0.96
Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw (2011) 0.95
Biotechnology and Medicare's new technology policy: lessons from three case studies. Health Aff (Millwood) (2006) 0.94
Sample features associated with success rates in population-based EGFR mutation testing. J Thorac Oncol (2014) 0.93
Ancillary testing in lung cancer diagnosis. Pulm Med (2012) 0.92
Association of regional variation in primary care physicians' colorectal cancer screening recommendations with individual use of colorectal cancer screening. Prev Chronic Dis (2007) 0.92
Patient costs for medication abortion: results from a study of five clinical practices. Womens Health Issues (2006) 0.91
Is the prevalence of gatekeeping in a community associated with individual trust in medical care? Med Care (2003) 0.90
Differential role of estrogen receptor beta in early versus metastatic non-small cell lung cancer. Horm Cancer (2012) 0.90
Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer. Med Care (2011) 0.90
Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. Curr Drug Saf (2007) 0.88
Cost-utility of metal-on-metal hip resurfacing compared to conventional total hip replacement in young active patients with osteoarthritis. Value Health (2013) 0.88
Variation in screening mammography and Papanicolaou smear by primary care physician specialty and gatekeeper plan (United States). Cancer Causes Control (2004) 0.88
Docetaxel in non-small cell lung cancer: impact on quality of life and pharmacoeconomics. Drugs Aging (2007) 0.87
Medicare formulary coverage for top-selling biologics. Nat Biotechnol (2009) 0.87
Influence of patient preferences on the cost-effectiveness of screening for lynch syndrome. J Oncol Pract (2012) 0.87
Reliability and validity of the EQ-5D-5L compared to the EQ-5D-3L in patients with osteoarthritis referred for hip and knee replacement. Qual Life Res (2015) 0.86
Colorectal cancer screening differential costs for younger versus older Americans. Am J Prev Med (2006) 0.86
Economic evaluation of targeted cancer interventions: critical review and recommendations. Genet Med (2011) 0.85
Capacity building for assessing new technologies: approaches to examining personalized medicine in practice. Per Med (2010) 0.85
How affordable are targeted therapies in non-small cell lung cancer? Curr Treat Options Oncol (2011) 0.85
Functional outcomes for 2 years comparing hip resurfacing and total hip arthroplasty. J Arthroplasty (2012) 0.85
Second-hand smoke as a predictor of smoking cessation among lung cancer survivors. J Clin Oncol (2014) 0.85
Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC? J Thorac Oncol (2013) 0.84
Utilization of prophylactic cranial irradiation in patients with limited stage small cell lung carcinoma. Cancer (2010) 0.83
Provider practice models for and costs of delivering medication abortion -- evidence from 11 US abortion care settings. Contraception (2006) 0.83
Angiotensin receptor blockers on the formularies of Medicare drug plans. J Gen Intern Med (2007) 0.83
The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada. Health Policy (2007) 0.83
Derivation of utility values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire values in lung cancer. J Thorac Oncol (2010) 0.83
Health technology assessment and private payers's coverage of personalized medicine. Am J Manag Care (2011) 0.83
An empirical comparison of methods for analyzing correlated data from a discrete choice survey to elicit patient preference for colorectal cancer screening. BMC Med Res Methodol (2012) 0.82
Assessing the impact of censoring of costs and effects on health-care decision-making: an example using the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Value Health (2007) 0.81
Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. Cancer (2009) 0.81
Do economic evaluations of targeted therapy provide support for decision makers? Am J Manag Care (2011) 0.81
Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada. J Thorac Oncol (2014) 0.81
Genomic testing and therapies for breast cancer in clinical practice. J Oncol Pract (2011) 0.81
Genomic testing and therapies for breast cancer in clinical practice. Am J Manag Care (2011) 0.81
Initial treatment strategies and outcomes for multifocal bronchioloalveolar carcinoma. Clin Lung Cancer (2009) 0.80
Factors contributing to adjuvant therapy decisions. J Thorac Oncol (2008) 0.80
Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care. Breast Cancer Res Treat (2011) 0.80
End-of-life home care utilization and costs in patients with advanced colorectal cancer. J Community Support Oncol (2014) 0.80
Guidelines for health technologies: specific guidance for oncology products in Canada. Value Health (2012) 0.80
Evaluating the primary-to-specialist referral system for elective hip and knee arthroplasty. J Eval Clin Pract (2013) 0.80